conventional antibiotic therapy is often encountered because infected cells prevent drug permeation or the drug concentration is too low at the site of resident bacteria. New paradigms are therefore urgently needed for intracellular anti-infective therapy. Here, a novel therapeutic was developed for targeted delivery of antibiotics into bacteria-infected macrophages to improve drug accumulation in intracellular
is not enough: Terminal alkenes are used as chemical reporters and ligation partners for 1,2,4,5‐tetrazines in a Diels–Alder reaction with inverse electron demand (DARinv). Combination with strain‐promoted azide–alkyne cycloaddition (SPAAC) allows the visualization of two different glycan structures in one experiment.
Disclosed is a process for the preparation of a glucosamine acid addition salt from fructose and ammonia or an ammonia source such as an ammonium compound by contacting fructose and ammonia or an ammonia source in the presence of (i) a solvent comprising about 25 to 100 weight percent water and 75 to 0 weight percent of an inert, organic, water-miscible solvent at a
W
W
pH or
S
W
pH of about 1 to 6; or (ii) a solvent comprising about 75 to 100 weight percent of an inert, organic, water-miscible solvent and 0 to 25 weight percent water at a
W
W
pH or
S
W
pH of about 1 to 10. A mannosamine acid addition salt also is produced as a co-product of the process.
The present invention features a chemoselective ligation reaction that can be carried out under physiological conditions. In general, the invention involves condensation of a specifically engineered phosphine, which can provide for formation of an amide bond between the two reactive partners resulting in a final product comprising a phosphine moiety, or which can be engineered to comprise a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine byproduct and producing a native amide bond in the final product. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).
METHOD FOR IMAGING CELL USING FLUORESCENCE-LABELED SUGAR DERIVATIVE HAVING COUMARIN DERIVATIVE BOUND THERETO, AND IMAGING AGENT
申请人:Hirosaki University
公开号:US20150369797A1
公开(公告)日:2015-12-24
The present invention has an object of providing a sugar derivative emitting blue fluorescence color which can be used for imaging of cells or intracellular molecules and a method for imaging cells using the derivative. Further, the present invention has an object of providing a method for detecting cancer cells at high accuracy by imaging, and an imaging agent used for this method. The present invention provides a fluorescently labeled sugar derivative having 3-carboxy-6,8-difluoro-7-hydroxycoumarin or 3-carboxymethyl-6,8-difluoro-7-hydroxy-4-methylcoumarin as a fluorescent molecular group in its molecule, and a cell imaging agent and an imaging method using the derivative. Further, the present invention provides an imaging agent and an imaging method for cancer cells using an L-glucose derivative having the above-described fluorescent molecular group in its molecule.